Latest Insider Transactions at Stoke Therapeutics, Inc. (STOK)
This section provides a real-time view of insider transactions for Stoke Therapeutics, Inc. (STOK). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Stoke Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Stoke Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2021
|
Apple Tree Partners Iv, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
17,161,713
-100.0%
|
-
|
|
Jun 01
2021
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
575
-100.0%
|
$22,425
$39.43 P/Share
|
|
Jun 01
2021
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
575
+50.0%
|
$1,150
$2.19 P/Share
|
|
Mar 02
2021
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
5,195
-10.3%
|
$322,090
$62.99 P/Share
|
|
Mar 02
2021
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
5,195
+16.37%
|
$0
$0.6 P/Share
|
|
Mar 01
2021
|
Arthur A Levin |
SELL
Open market or private sale
|
Direct |
12,500
-80.17%
|
$750,000
$60.84 P/Share
|
|
Mar 01
2021
|
Arthur A Levin |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+39.06%
|
$0
$0.47 P/Share
|
|
Feb 23
2021
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
5,000
-89.25%
|
$290,000
$58.6 P/Share
|
|
Feb 23
2021
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+47.16%
|
$20,000
$4.48 P/Share
|
|
Feb 22
2021
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
25,000
-55.7%
|
$1,475,000
$59.32 P/Share
|
|
Feb 22
2021
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+49.41%
|
$100,000
$4.48 P/Share
|
|
Feb 19
2021
|
Arthur Tzianabos Interim Executive Chair |
SELL
Open market or private sale
|
Direct |
10,000
-100.0%
|
$600,000
$60.67 P/Share
|
|
Feb 19
2021
|
Arthur Tzianabos Interim Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$20,000
$2.19 P/Share
|
|
Jan 06
2021
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
32
-100.0%
|
$1,824
$57.14 P/Share
|
|
Jan 04
2021
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-63.24%
|
$336,300
$59.26 P/Share
|
|
Jan 04
2021
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+49.86%
|
$11,400
$2.19 P/Share
|
|
Dec 30
2020
|
Edward M. Md Kaye |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+50.0%
|
$0
$0.6 P/Share
|
|
Dec 28
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
149
-0.69%
|
$8,642
$58.73 P/Share
|
|
Dec 28
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+27.12%
|
$0
$0.6 P/Share
|
|
Dec 21
2020
|
Barry Ticho CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,365
-0.26%
|
$77,805
$57.93 P/Share
|
|
Dec 21
2020
|
Barry Ticho CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,365
+0.78%
|
$2,730
$2.19 P/Share
|
|
Dec 18
2020
|
Edward M. Md Kaye |
SELL
Open market or private sale
|
Direct |
5,194
-100.0%
|
$311,640
$60.0 P/Share
|
|
Dec 18
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
8,015
-100.0%
|
$480,900
$60.0 P/Share
|
|
Dec 18
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,015
+50.0%
|
$0
$0.6 P/Share
|
|
Dec 17
2020
|
Edward M. Md Kaye |
SELL
Open market or private sale
|
Direct |
19,806
-79.22%
|
$1,188,360
$60.0 P/Share
|
|
Dec 17
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
41,985
-100.0%
|
$2,519,100
$60.0 P/Share
|
|
Dec 17
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,985
+50.0%
|
$0
$0.6 P/Share
|
|
Dec 01
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-62.73%
|
$285,000
$50.85 P/Share
|
|
Dec 01
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|
|
Nov 27
2020
|
Edward M. Md Kaye |
SELL
Open market or private sale
|
Direct |
12,152
-32.71%
|
$607,600
$50.0 P/Share
|
|
Nov 25
2020
|
Edward M. Md Kaye |
SELL
Open market or private sale
|
Direct |
12,848
-25.7%
|
$642,400
$50.0 P/Share
|
|
Nov 24
2020
|
Apple Tree Partners Iv, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
375,000
+2.14%
|
$14,625,000
$39.0 P/Share
|
|
Nov 24
2020
|
Seth Loring Harrison |
BUY
Open market or private purchase
|
Indirect |
375,000
+2.14%
|
$14,625,000
$39.0 P/Share
|
|
Nov 23
2020
|
Arthur Tzianabos Interim Executive Chair |
SELL
Open market or private sale
|
Direct |
20,000
-70.66%
|
$920,000
$46.38 P/Share
|
|
Nov 23
2020
|
Arthur Tzianabos Interim Executive Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+50.0%
|
$40,000
$2.19 P/Share
|
|
Nov 10
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
50,000
-100.0%
|
$2,250,000
$45.0 P/Share
|
|
Nov 10
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+35.58%
|
$50,000
$1.4 P/Share
|
|
Nov 04
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
33,268
-68.43%
|
$1,363,988
$41.14 P/Share
|
|
Nov 04
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,268
+49.55%
|
$133,072
$4.48 P/Share
|
|
Nov 03
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
1,732
-74.21%
|
$67,548
$39.84 P/Share
|
|
Nov 03
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
1,732
+42.6%
|
$6,928
$4.48 P/Share
|
|
Nov 02
2020
|
Huw M. Nash Chief Business Officer |
SELL
Open market or private sale
|
Direct |
5,700
-77.75%
|
$210,900
$37.29 P/Share
|
|
Nov 02
2020
|
Huw M. Nash Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+50.0%
|
$11,400
$2.19 P/Share
|
|
Nov 02
2020
|
Stephen J Tulipano Former CFO |
SELL
Open market or private sale
|
Direct |
35,000
-63.35%
|
$1,295,000
$37.7 P/Share
|
|
Nov 02
2020
|
Stephen J Tulipano Former CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
35,000
+49.57%
|
$140,000
$4.48 P/Share
|
|
Oct 19
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
32,000
-44.66%
|
$1,216,000
$38.03 P/Share
|
|
Oct 19
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
32,000
+22.07%
|
$32,000
$1.4 P/Share
|
|
Oct 16
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
5,851
-30.24%
|
$234,040
$40.0 P/Share
|
|
Oct 16
2020
|
Gene Liau EVP Research & Preclinical Dev |
BUY
Exercise of conversion of derivative security
|
Direct |
5,851
+23.22%
|
$0
$0.6 P/Share
|
|
Oct 13
2020
|
Gene Liau EVP Research & Preclinical Dev |
SELL
Open market or private sale
|
Direct |
1,649
-10.89%
|
$65,960
$40.0 P/Share
|